Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Notes Payables (2019 - 2020)

Historic Notes Payables for Protalix BioTherapeutics (PLX) over the last 2 years, with Q4 2020 value amounting to $4.1 million.

  • Protalix BioTherapeutics' Notes Payables fell 499.88% to $4.1 million in Q4 2020 from the same period last year, while for Dec 2020 it was $4.1 million, marking a year-over-year decrease of 499.88%. This contributed to the annual value of $4.1 million for FY2020, which is 499.88% down from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Notes Payables of $4.1 million as of Q4 2020, which was down 499.88% from $4.3 million recorded in Q3 2020.
  • In the past 5 years, Protalix BioTherapeutics' Notes Payables registered a high of $4.3 million during Q4 2019, and its lowest value of $4.1 million during Q4 2020.